培美曲塞治疗复治进展期非小细胞肺癌  

Clinical observation of Alimta monotherapy in treatment of advanced non-small cell lung cancer

作　　者：王海燕[1] 屈涛[1] 屈凤莲[1] 

机构地区：[1]中国医学科学院中国协和医科大学肿瘤医院内科,北京100021

出　　处：《中国肺癌杂志》2008年第3期435-437,共3页Chinese Journal of Lung Cancer

摘　　要：背景与目的培美曲塞在肺癌治疗中应用较少,本研究旨在观察培美曲塞单药治疗复治进展期非小细胞肺癌患者的临床疗效和毒副反应。方法对23例复治进展期非小细胞肺癌患者采用培美曲塞单药化疗,所有病例均有可测量和评价病灶。培美曲塞500mg/m2,静脉滴注,第1天,每21天重复一次,至少治疗2周期。结果共完成化疗67周期,中位数3周期,有效率8.69%,稳定率47.82%。中位无进展生存期2.7个月,中位生存期8.0个月,1年生存率26.08%(6/23)。主要毒副反应为骨髓抑制,白细胞降低率78.26%,均为Ⅰ-Ⅱ度;血小板降低率8.69%,均为Ⅰ度。结论培美曲塞单药治疗复治进展期非小细胞肺癌患者疗效肯定,毒副反应轻,患者耐受性好。Background and objective The use of alimta is very little in the treatment of lung cancer. The aim of this work is to study the clinical effect and toxicity of alimta monotherapy in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods 23 patients with advanced diagnosed by pathology or cytology were enrolled into the study. The patients received alimta 500 mg/m^2 on dl, intravenously every 3 weeks and were evaluated effect after 2 cycles. Results 67 cycles of the chemotherapy were completed and the median cycles of the treatment were 3. The total response rate was 8.69%. The stable disease rate was 47.82%. The median time to diease progression was 2.7 months and the median survival time was 8.0 months. The 1-year survival rate was 26.08%. The main toxicity was hematological toxicity. Grade Ⅰ - Ⅱ leukopenia was seen in 18 patients （78.26%）. Grade Ⅰ thrombocytopenia was seen in 2 patient （8.69%）. Conclusion Alimta is an effective therapy for the patients with advanced NSCLC. The efficacy improved and the toxicities can be tolerated.

关 键 词：肺肿瘤 培美曲塞 化疗 

分 类 号：R734.2[医药卫生—肿瘤]